Ancilia Biosciences develops virus-resistant live bacterial products for human health and other applications using proprietary CRISPR-based technologies. Its CoVE™ platform identifies and characterizes viral phages, and its EPIC platform leverages bacteria’s natural CRISPR function to produce live biotherapeutics and microbial products with immunity to key viral pathogens. The company has achieved proof-of-concept and holds key patents protecting these inventions. Led by CEO Alexandra Sakatos and co-founded by Dr. Rodolphe Barrangou and David Paez-Espino, the team combines expertise in CRISPR, virology, and bioinformatics. Ancilia intends to use the $4.2M financing to expand operations and its R&D sector. The company is based in New York City.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2024